著者

Toru Maruyama Hayata Uesako

出版者

The Japanese Society of Internal Medicine

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

pp.2298-23, (Released:2023-08-23)

参考文献数

37

---

Vaccination against COVID-19 has raised concerns about myocarditis in young men, as out-of-hospital cardiac arrest (OHCA) or sudden death after vaccination has been reported sporadically. Common features of these cases are occurrence in young men, within a few weeks after vaccination, in patients with no structural heart diseases. Cases of unexplained nocturnal death showed fibrotic or hypertrophied myocardium, and one case of OHCA presented ventricular fibrillation (VF) triggered by a prominent J wave on an automated external defibrillator and histopathologic findings compatible with myocarditis. Both myocarditis and J waves are prevalent in young men, and these cases imply that myocarditis augments J waves, which trigger VFs, and primary electrical disorders are a leading cause of death. To prevent such issues, artificial intelligence (AI)-assisted interpretation of historical electrocardiogram findings may help predict future J wave formation leading to VF, as digital ECG findings are well suited for AI interpretation.

著者

Katsushige Ono Yu-ki Iwasaki Masaharu Akao Takanori Ikeda Kuniaki Ishii Yasuya Inden Kengo Kusano Yoshinori Kobayashi Yukihiro Koretsune Tetsuo Sasano Naokata Sumitomo Naohiko Takahashi Shinichi Niwano Nobuhisa Hagiwara Ichiro Hisatome Tetsushi Furukawa Haruo Honjo Toru Maruyama Yuji Murakawa Masahiro Yasaka Eiichi Watanabe Takeshi Aiba Mari Amino Hideki Itoh Hisashi Ogawa Yasuo Okumura Chizuko Aoki-Kamiya Jun Kishihara Eitaro Kodani Takashi Komatsu Yusuke Sakamoto Kazuhiro Satomi Tsuyoshi Shiga Tetsuji Shinohara Atsushi Suzuki Shinya Suzuki Yukio Sekiguchi Satoshi Nagase Noriyuki Hayami Masahide Harada Tadashi Fujino Takeru Makiyama Mitsunori Maruyama Junichiro Miake Shota Muraji Hiroshige Murata Norishige Morita Hisashi Yokoshiki Koichiro Yoshioka Kenji Yodogawa Hiroshi Inoue Ken Okumura Takeshi Kimura Hiroyuki Tsutsui Wataru Shimizu on behalf of the Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

pp.CJ-20-1212, (Released:2022-03-11)

参考文献数

998

被引用文献数

44

著者

Isamu Kaneda Toru Maruyama

出版者

JAPANESE SOCIETY OF BIORHEOLOGY

雑誌

Journal of Biorheology (ISSN:18670466)

巻号頁・発行日

vol.36, no.1, pp.1-2, 2022 (Released:2022-07-29)

参考文献数

2

著者

Yu Ishima Toru Maruyama Masaki Otagiri Victor T. G. Chuang Tatsuhiro Ishida

出版者

The Pharmaceutical Society of Japan

雑誌

Chemical and Pharmaceutical Bulletin (ISSN:00092363)

巻号頁・発行日

vol.70, no.5, pp.330-333, 2022-05-01 (Released:2022-05-01)

参考文献数

48

被引用文献数

21

---

Albumin, the most abundant protein in human serum, is applied to various diseases as a drug delivery carrier because of its superior blood retention, high biocompatibility, and a wide variety of drug binding abilities. Albumin is known to distribute widely in the blood and various interstitial fluids and organs. Different albumin receptors skillfully regulate the distribution characteristics of albumin in the body. Albumin receptors are a group of diverse proteins, such as FcRn, gp60, gp18, megalin, cubilin, SPARC, and CD36. Their tissue distributions in vivo are unique, with different albumin’s recognition sites. Therefore, the distribution of albumin in vivo is ingeniously controlled by these multiple albumin receptors. Reevaluation of these albumin receptors opens up new possibilities for applying albumin as a drug delivery carrier. If the tissue distributions of albumin receptors were known and the albumin recognition site of the receptor was identified, organ-specific active targeting would be possible. In this review, we would like to scrutinize what is currently known and share information to develop next-generation albumin carriers that focus on interactions with albumin receptors.

著者

Motoko Tanaka Shigeyuki Miyamura Tadashi Imafuku Yuna Tominaga Hitoshi Maeda Makoto Anraku Keishi Yamasaki Daisuke Kadowaki Yu Ishima Hiroshi Watanabe Tomoko Okuda Kazuko Itoh Kazutaka Matsushita Masafumi Fukagawa Masaki Otagiri Toru Maruyama

出版者

公益社団法人日本薬学会

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.39, no.6, pp.1000-1006, 2016-06-01 (Released:2016-06-01)

参考文献数

29

被引用文献数

9

---

A ferric citrate formulation for treating hyperphosphatemia is a new therapeutic that not only suppresses the accumulation of phosphorus in patients with chronic kidney disease-mineral bone disorders (CKD-MBD), but also ameliorates anemia caused by iron deficiency. In contrast, it has been demonstrated that intravenous iron injection markedly increases oxidative stress. This study was designed to investigate the effect of a ferric citrate formulation on oxidative stress in CKD-MBD patients receiving hemodialysis therapy. Fifteen CKD-MBD patients undergoing dialysis were enrolled in this study. The patients were orally administered a ferric citrate formulation for 6 months. Their plasma phosphorus concentrations remained unchanged with the switch from other phosphorus adsorbents to the ferric citrate formulation. In addition, the ferric citrate formulation generally allowed for dose reduction of an erythropoiesis stimulating agent with an increased hematopoietic effect. The average values of plasma ferritin level increased after the introduction of a ferric citrate formulation, but did not exceed 100 (ng/mL). Interestingly, oxidative stress markers did not increase significantly, and anti-oxidative capacity was not significantly decreased at 6 months after the drug administration. Similarly, no change was observed in any inflammation markers. The ferric citrate formulation induces negligible oxidative stress in CKD-MBD patients receiving dialysis under the present clinical condition.

著者

Michinari Hieda Toru Maruyama

出版者

JAPANESE SOCIETY OF BIORHEOLOGY

雑誌

Journal of Biorheology (ISSN:18670466)

巻号頁・発行日

vol.36, no.1, pp.12-22, 2022 (Released:2022-07-29)

参考文献数

104

---

Left ventricular assist device (LVAD) is an important therapeutic option for patients with end-stage advanced heart failure. LVAD can reduce cardiovascular death and improve the quality of life in patients with end-stage advanced heart failure. However, as LVAD-implanted patients increase and survival becomes prolonged, many patients experience serious complications. Major complications of LVAD include ischemic and hemorrhagic strokes, bleeding complications, device thrombosis, right heart failure, and LVAD related infections. These complications lead to worse mortality in patients with LVAD. In particular, cerebrovascular events and gastrointestinal bleeding are the most dreaded complications. High molecule weight multimers of von Willebrand factor (vWF-HMWM) play an essential role in platelet adhesion and aggregation, but high shear stress caused by LVAD pump diminishes the vWF-HMWM. In fact, in response to the shear stress of LVAD, vWF exposes cleavage domains of ADAMTS 13 to form smaller multimeric molecules. Therefore, in many patients with LVAD, the vWF reduces its large multimers and lowers the ability to bind sufficiently to platelets and sub-endothelial collagen, resulting in the acquired von Willebrand syndrome. Thus, in LVAD patients with acquired von Willebrand syndrome, vWF function is impaired, and this impairment is associated with hemocompatibility-related adverse events. Based on hemorheology, this review focuses on the pathophysiology of acquired von Willebrand syndrome and its management in patients with LVAD.